An Apple Watch-guided event-triggered anticoagulation strategy reduced DOAC exposure by 94.6% compared with continuous therapy in post-ablation atrial fibrillation patients, with no ischemic events.
Does wearable-guided event-triggered anticoagulation reduce DOAC exposure in post-ablation atrial fibrillation patients?
Wearable-guided, event-triggered anticoagulation after AF ablation shows promise for safely reducing unnecessary DOAC exposure, inviting a reconsideration of static, risk-score-based guidelines.
Advances in continuous rhythm monitoring challenge this static approach.Thromboembolic risk appears to relate not only to baseline clinical risk factors but also to AF burden. 5At same time, continued direct oral anticoagulant (DOAC) carries bleeding risk, even in relatively low-risk populations. 6Thus, tension persists between preventing stroke and avoiding unnecessary anticoagulation, particularly after apparently successful pulmonary vein isolation (PVI). Catheter ablation is an established rhythm-control strategy for atrial fibrillation (AF), improving symptoms and quality of life and potentially influencing long-term outcomes. 1However, the optimal anticoagulation management after ablation remains controversial.Current guidelines recommend that decisions regarding oral anticoagulation (OAC) after ablation be guided by thromboembolic risk scores rather than rhythm status, given the often asymptomatic and intermittent nature of AF recurrence. 2-4This conservative paradigm prioritizes stroke prevention but does not incorporate real-time rhythm information.
Suzuki et al. (Thu,) conducted a editorial in Atrial fibrillation post-ablation (n=50). Apple Watch-guided event-triggered anticoagulation vs. Continuous DOAC therapy was evaluated on DOAC exposure reduction. An Apple Watch-guided event-triggered anticoagulation strategy reduced DOAC exposure by 94.6% compared with continuous therapy in post-ablation atrial fibrillation patients, with no ischemic events.